

# **TRANSCAVAL AORTIC VALVE IMPLANTATION**

# Mauro De Benedictis



Azienda Ospedaliera Ordine Mauriziano di Torino



# Conflict of Interest: None



# Alternative Access for TAVI: What we don't know


TURIN

October

24<sup>th</sup>-26<sup>th</sup>

2019

• Are the worse outcomes seen with nontransfemoral access related to the underlying morbidities or to the access method itself?







TURIN October 24<sup>th</sup>-26<sup>th</sup> 2019

# Convertion of trans-thoracic access into more «transfemoral like» procedures should improve outcomes


- Transcaval is transfemoral
- TC only needs conscious sedation
- TC is a transvenous procedure
- Allows rapid ambulation and reduces lengh of stay
- *Proctorship recommended!*





TURIN October 24<sup>th</sup>-26<sup>th</sup> 2019

# Transcaval Access for TAVI: Reassuring Physiology




- IVC is usually close to aorta without significant intervening structures.
- Interstitial pressure in retroperitonal space is higher than vein.
- Aortic bleeding decompresses through a hole in IVC.






# **Two New Concepts**







TURIN

October

 $24^{\text{th}}\text{-}26^{\text{th}}$ 

2019

## Transcatheter Electrosurgery



# **31** GIORNATE CARDIOLOGICHE TORINESI

## Key elements

**Obtain CT-based Treatment Plan** 

# Calcium-free target


Nothing interposed

Away from renal and iliacs

# Bailout plan



ID	Type Label	Valu
1	Ellipse Min. Ø	5.5 n
2	Ellipse Min. Ø	10.0



1E 10 LAO 80 RAO L3.1



A	vg. Ø	15.4 mm	bifurcation
100" al: 0°			Target dista
al: 0°	. 12		Endograft b
		0 K (	Femoral to
	63	A BAL	Mesenterio
	right R		Caveat & Co
	1E 2E		13-1-


Recommendation (CA-TAVR eligibility)	Favorable; Uncertain; Unfavorable		
Aortic Ca <sup>2+</sup> / thickening / ectasia	Aortic calcium grade 2		
Target entry site lumbar vertebra	Mid Body L3 (L3.0)		
Orthogonal projection	Anteroposterior		
Caval-aortic distance X-Y	6 mm		
Interposed structures	none		
Nearby structures	Bowel anterior to target		
Caval lumen diameter	23 mm		
Aortic lumen diameter (+3/0/-1.2cm)	15 mm / 16 mm / 14 mm		
Target distance above aorto-iliac bifurcation	12 mm		
Target distance below R renal artery	75 mm		
Endograft bailout limb access	RCIA 5.2 mm, LCIA 3.0 mm		
Femoral to target centerline distance	24 cm		
Mesenterics	Celiac patent; SMA patent		
Caveat & Comments	15x20 mm target window		


### TURIN October 24<sup>th</sup>-26<sup>th</sup> 2019



# **31** GIORNATE CARDIOLOGICHE TORINESI

Aligning, Crossing, Snaring & Advancing





TURIN

October

 $24^{th}-26^{th}$ 


2019





Closure: Fundamental Pathophysiology Principle

- A venous sink/sump is required to decompress arterial hemorrage
- The hole in IVC must not be occluded unless the hole in the aorta is occluded
- Only withdraw aortic sheath COMPLETELY into cava



TURIN

October

24<sup>th</sup>-26<sup>th</sup>


2019



# All further remedies are endovascular ( $\geq$ 9F)!







TURIN

October

 $24^{\text{th}}\text{-}26^{\text{th}}$ 

2019

### Aortic stent graft





## D.E., 81 yo female

STS score morbidity or mortality 20.6 %, mortality 5.5% EUROSCORE II 11.7 %

81 Kg x 156 cm

Cardiovascular risk factors:

Hypertension, diabetes mellitus, dyslipidemia, obesity, OSAS

#### **Comorbidity:**

PAD, sideropenic anemia, previous TEA ICA dx. Previous hysterectomy (uterus carcinoma). COPD. CKD (eGFR 35 ml/min/1.73 m2), hip arthrosis.

#### **Cardiological anamnesis:**

Known hypertensive cardiopathy Previous hospitalizations for AHF managed with diuretics Worsening NYHA III class Discovery of **severe aortic stenosis** (AVA 0.8 cm2, Gradient max/med 62/42 mmHg). EF 56%





















ID Type Label	Value	25 Type Label	Value
1 Diamatar (Min/Max) Min. Ø	14.6 mm	1 Diameter (MitcMax) Mits E	14.0 mm
Mun. O	15.5 mm	Max. D	TAJImm
Aug. 0	12.5 mm	Avg. 0	54.1 mm